The Next
Generation
Triple Agonist
Retatrutide simultaneously activates three metabolic receptors — GIP, GLP-1, and glucagon. In our full Retatrutide New Zealand guide, we break down how this triple agonist works, how it compares to existing GLP-1 drugs, and what current clinical data means for metabolic research in Aotearoa.
TRIUMPH-4: 28.7% Mean Weight Loss at 68 Weeks
Breaking down Lilly’s first successful Phase 3 readout in obesity with knee osteoarthritis — the numbers, the caveats, and what it means.
Triple Receptor Agonism: Why the GCGR Target Changes Everything
How glucagon receptor activation sets retatrutide apart from existing GLP-1 therapies.
Research-Use Peptides in New Zealand: A Practical Overview
Regulatory landscape, clinical context, and what New Zealand researchers need to understand.
Three Targets.
One Molecule.
Where semaglutide and tirzepatide act on one or two receptors, retatrutide (LY3437943) is a once-weekly injectable peptide that simultaneously activates the GIP, GLP-1, and glucagon receptors — the first of its kind to reach late-stage clinical development.
The additional glucagon receptor component may drive significantly greater energy expenditure and fat oxidation compared to GLP-1 monotherapy, which researchers believe may explain the higher weight-loss figures seen in trials.
For a deeper comparison, see our retatrutide vs semaglutide comparison and our retatrutide vs tirzepatide analysis.
-
GLPreceptorGLP-1 Receptor AgonismReduces appetite and food intake. Slows gastric emptying. Shared mechanism with semaglutide and tirzepatide. Learn more in our GLP-1 mechanism guide.
-
GIPreceptorGIP Receptor AgonismEnhances insulin secretion and may influence GLP-1 receptor sensitivity. Also active in tirzepatide.
-
GCGreceptorGlucagon Receptor AgonismThe third target — associated with increased energy expenditure, hepatic fat changes, and retatrutide’s distinct research profile.
Latest Research
& Analysis
All Guides
Retatrutide New Zealand: Full Research Guide
A complete New Zealand-focused overview of retatrutide research, mechanisms, trial context, and where the compound sits within the wider GLP-1 landscape.
Retatrutide vs Tirzepatide: Triple vs Dual Agonist
A direct comparison of retatrutide and tirzepatide, including receptor targets, weight-loss trial context, and mechanism differences.
Retatrutide vs Semaglutide: Next-Gen GLP-1 Research
How retatrutide compares with semaglutide across receptor activity, research outcomes, and clinical development.
The numbers
behind the latest TRIUMPH headline
This page includes TRIUMPH-4 topline Phase 3 context alongside earlier published Phase 2 research. This site presents research information only. Individual outcomes vary. Not medical advice.
Retatrutide research, comparisons, and GLP-1 science.
Start with the complete Retatrutide New Zealand guide, then explore how retatrutide compares with established metabolic research compounds including semaglutide and tirzepatide.
For a deeper mechanism breakdown, read our GLP-1 mechanism of action guide. You can also browse the full retatrutide guides library. For researchers looking into availability, see our where to buy retatrutide NZ guide, which covers supplier transparency, COA checks, and research-use sourcing red flags.
Retatrutide New Zealand Guide
The core NZReta guide covering retatrutide research, mechanisms, and New Zealand context.
Read guide →Retatrutide vs Semaglutide
Compare triple agonist retatrutide with GLP-1 semaglutide across mechanism and research data.
Compare →Retatrutide vs Tirzepatide
Triple agonist vs dual agonist: a direct comparison for metabolic research context.
Compare →GLP-1 Mechanism of Action
Understand GLP-1, GIP, and glucagon receptor activity behind next-generation metabolic research.
Learn mechanism →All Retatrutide Guides
Browse the full NZReta research library and all published retatrutide-related guides.
View all guides →Where to Buy Retatrutide in NZ
A research-focused sourcing guide covering supplier transparency, COA verification, and red flags for New Zealand researchers.
View guide →Is My Retatrutide Fake?
Learn how to identify fake, underdosed, or unverified retatrutide using COAs, mass spec, batch matching, and supplier transparency checks.
Read guide →Retatrutide Clinical Trials NZ
A full breakdown of retatrutide clinical trial data including Phase 2 studies, TRIUMPH, TRANSCEND, obesity outcomes, and future development.
View trials →